New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2012
17:24 EDTSNY, ABT, MRK, GS, GSKGoldman Sachs hired to explore Bausch & Lomb sale, Bloomberg reports
Goldman Sachs (GS) has been hired by Warburg Pincus to explore a sale of Bausch & Lomb, the company's eye-care division, and Warburg is said to be seeking at least $10B for the business, according to a Bloomberg report that cites sources familiar with the matter. The report says that Goldman contacted Sanofi (SNY), GlaxoSmithKline (GSK), and Merck (MRK) this month, and that Abbot Laboratories (ABT) will be among the other companies contacted, according to a source. Reference Link
News For GS;ABT;GSK;MRK;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
August 27, 2015
06:46 EDTGSFed ups scrutiny of U.S. bank payment systems, WSJ reports
Subscribe for More Information
06:34 EDTGSBanks, investors may suffer from margin calls, WSJ reports
Subscribe for More Information
06:23 EDTGSGoldman hiring 'several hundred' employees for Warsaw units, Reuters reports
Subscribe for More Information
August 26, 2015
17:06 EDTGSKGilead AMBITION study results published in New England Journal of Medicine
Gilead Sciences (GILD) announced detailed results from the AMBITION study. In AMBITION, conducted in collaboration with GlaxoSmithKline (GSK), combination therapy with Letairis and tadalafil reduced the risk of clinical failure by 50% compared to the pooled Letairis and tadalafil monotherapy arm. These data were published in The New England Journal of Medicine. Letairis, a selective endothelin type-A receptor antagonist, and tadalafil, a PDE5 inhibitor, are each approved in the United States, the European Union and other countries as once-daily treatments for patients with pulmonary arterial hypertension with WHO/NYHA functional class II and III symptoms. Letairis is indicated in the U.S. to improve exercise ability and delay clinical worsening and in the EU under the tradename Volibris to improve exercise capacity. Tadalafil 40 mg is indicated in the U.S. and the EU to improve exercise ability and capacity, respectively. Preclinical data have suggested these therapies may have synergistic effects. However, combination use with Letairis and tadalafil is currently not approved.
08:53 EDTMRKMerck management to meet with SunTrust
Subscribe for More Information
August 24, 2015
13:15 EDTGSKFDA expands use of Novartis' Promacta to include children ages 1 and older
Ligand Pharmaceuticals (LGND) announced that the FDA has approved an expanded use for Promacta, a Novartis (NVS) product, to include children 1 year of age and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was acquired by Novartis in March from GlaxoSmithKline (GSK). Promacta was discovered as a result of research collaboration between GSK and Ligand Pharmaceuticals and was developed by GSK. The updated label also includes a new oral suspension formulation of Promacta that is designed for younger children who may not be able to swallow tablets. Promacta was approved by the FDA as a tablet formulation in June 2015 for children 6 years of age and older and in 2008 for use in adult patients with the same condition. The label expansion of Promacta was based on data from two double-blind, placebo-controlled trials, including the largest Phase 3 clinical trial in this patient population. Treatment with Promacta significantly increased and sustained platelet counts among pediatric patients with chronic ITP with an insufficient response to prior chronic ITP therapies, and some patients taking concomitant ITP medications were able to reduce or discontinue their use of these medications, primarily corticosteroids. Promacta should be used only in those whose degree of thrombocytopenia and clinical condition increase the risk for bleeding.
05:47 EDTGSStocks with implied volatility movement; DIA GS
Stocks with implied volatility movement; Diamonds Fund ETF (DAI) 25, Goldman Sachs (GS) 31 according to iVolatility.
August 23, 2015
12:35 EDTMRKBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
05:44 EDTMRKStocks with implied volatility movement; DIS MRK
Subscribe for More Information
05:25 EDTGSKNovartis acquires all remaining rights to Ofatumumab from GSK
Novartis (NVS) announced that it has entered into an agreement to acquire all remaining rights to Ofatumumab from GlaxoSmithKline (GSK). Ofatumumab, a fully human monoclonal antibody which targets CD20, is being developed for relapsing remitting multiple sclerosis, or RRMS, and other autoimmune indications. Novartis previously acquired the rights to Ofatumumab for oncology indications and it is marketed under the brand name Arzerra. Novartis will be responsible for the worldwide development, regulatory and commercialization activities for Ofatumumab. Under the terms of the agreement, Novartis will make an initial upfront payment of $300M to GSK for the acquisition of the compound and a further payment of $200M payable following the start of a phase III study in MS by Novartis. Upon completion of pre-determined milestones, contingent payments of up to $534M may be made. Novartis will also pay royalties of up to 12% to GSK on any future net sales of Ofatumumab in autoimmune conditions.
August 20, 2015
11:33 EDTSNY, MRKLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
08:38 EDTMRKMerck says to present new analyses from IMPROVE-IT study
Subscribe for More Information
06:07 EDTGSSamsung Bioepis picks Citi, Goldman as lead managers for IPO, Reuters says
Samsung Bioepis has selected Citigroup (C) and Goldman Sachs (GS) as the lead managers for its planned listening on Nasdaq next year, a source tells Reuters. Morgan Stanley (MS) and Credit Suisse (CS) will also take part in the listing for Samsung's (SSNLF) biosimilar drug development arm, the source says. Reference Link
August 19, 2015
14:42 EDTGSBanks cooperate on data company to lower costs, WSJ says
Subscribe for More Information
14:25 EDTGSCoca-Cola has option for outright purchase of Suja, Bloomberg says
Subscribe for More Information
August 18, 2015
13:14 EDTGSNY court rules Goldman must face Abacus suit, Bloomberg reports
Subscribe for More Information
12:13 EDTMRKMerck recalls Temodar, Temozolomide bottles with cracked caps
Subscribe for More Information
08:03 EDTMRKMerck says FDA accepts sBLA for Keytruda
Subscribe for More Information
06:45 EDTGSNine banks agree to $2B settlement for currency market rigging, FT says
Subscribe for More Information
06:42 EDTGSGoldman buys stake in Piramal Realty, WSJ reports
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use